drugset / Trial / NCT04531332

Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

NCT04531332

RandomizedParallel-groupOpen-labelTreatment

Summary

The investigator's goal in this study is to determine the clinical efficacy and safety of continuous infusion in comparison with standard intermittent infusion.

Timeline

Start
2019-11-15
Primary completion
2021-09-15
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified 600 mg Intravenous
Subject Linezolid Other / unclassified 1200 mg Intravenous

Indications